Targeting signaling pathways in prostate cancer: mechanisms and clinical trials
East China Normal University · Shanghai Changzheng Hospital · +5 more institutions
Abstract
Abstract Prostate cancer (PCa) affects millions of men globally. Due to advances in understanding genomic landscapes and biological functions, the treatment of PCa continues to improve. Recently, various new classes of agents, which include next-generation androgen receptor (AR) signaling inhibitors (abiraterone, enzalutamide, apalutamide, and darolutamide), bone-targeting agents (radium-223 chloride, zoledronic acid), and poly(ADP-ribose) polymerase (PARP) inhibitors (olaparib, rucaparib, and talazoparib) have been developed to treat PCa. Agents targeting other signaling pathways, including cyclin-dependent kinase (CDK)4/6, Ak strain transforming (AKT), wingless-type protein (WNT), and epigenetic marks, have…
Citation impact
- FWCI
- 34.30
- Percentile
- 100%
- References
- 594
Authors
6- YHYundong HeCorresponding
East China Normal University
- WXWeidong Xu
Shanghai Changzheng Hospital
- YXYu‐Tian Xiao
Second Military Medical University, Shanghai Changzheng Hospital, Changhai Hospital
- HHHaojie Huang
Mayo Clinic
- DGDi GuCorresponding
First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University
Topics & keywords
- Olaparib
- Prostate cancer
- Enzalutamide
- Medicine
- Cancer research
- Pembrolizumab
- Androgen receptor
- Clinical trial
- Good health and well-being